Search

everythinglearnresearchcommunity

for

Search:↓

The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.

Blocking adenosine A2B receptor may prevent or treat hearing loss.

Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.

Adrenomedullin 2 stops cell growth and causes cell death in human hair follicles.

Too much AKR1C3 enzyme causes resistance to finasteride by increasing testosterone.

Minoxidil effectively lowers blood pressure and initially increases plasma renin activity without raising aldosterone levels.

Alpha-blockers are the most effective and widely used treatment for lower urinary tract symptoms, with minimal side effects.

Blocking CRF1 receptors improved male hormone levels and reduced testicular tumor size in men with a specific adrenal condition.

LY320236 is a strong blocker of two enzymes that change testosterone into dihydrotestosterone and might help treat conditions related to male hormones.

PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.

Adrenocorticotropic hormone inhibits growth and affects body composition in male rats.

MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.

New treatments for enlarged prostate are being developed to be more effective and have fewer side effects.

Finasteride reduces certain behaviors caused by D1-like receptor agonists but not by D2-like receptor agonists in mice.

PNU 157706 is a more effective treatment than finasteride for conditions caused by DHT, like enlarged prostate and hair loss.

New chemical compounds were made that effectively block an enzyme linked to prostate growth.

Blocking CYP17A1 enzyme may help improve certain brain function issues related to dopamine.

Compounds 15, 20, and 25 are strong inhibitors of human steroid 5α-reductase type 2.

Compound 4 is a promising treatment for hair loss with low toxicity.

New A-homo-B, 19-dinor steroids showed strong antiandrogenic activity without affecting the enzyme 5α-reductase or androgen receptor binding.

Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.

New compounds were made that effectively block a specific enzyme related to androgen conditions.

PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.

Researchers identified promising inhibitors for the BRD4 protein, including finasteride and amentoflavone.

Compound 7b is a promising candidate for treating benign prostatic hyperplasia and prostate cancer.

The research found that androgens help control blood flow in the rat prostate through a specific binding site.

Tamsulosin can worsen sleep apnea in some patients.